Evensen S A, Brinch L, Wisløff F
Tidsskr Nor Laegeforen. 1989 Jun 30;109(19-21):2004-6.
Adult patients with relapsed and refractory acute myelogenous leukemia usually demand further therapy aimed at achieving remission. The physician knows that life expectancy is limited. Care must be taken to choose a cytotoxic regimen where the potential gains outweigh the risks. Mitoxantrone and cytosine arabinoside were given in combination to 19 patients. Six achieved complete remission and increased survival. The side effects were acceptable.
复发难治性急性髓系白血病成年患者通常需要进一步治疗以实现缓解。医生知道其预期寿命有限。必须谨慎选择一种细胞毒性治疗方案，使其潜在获益大于风险。米托蒽醌和阿糖胞苷联合应用于19例患者。6例实现完全缓解并延长了生存期。副作用是可接受的。
